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eply
e thank Dr. Arbab-Zadeh for his interest in our paper (1). The
itle and the content of his letter show that he misinterprets the
ssence of our meta-analysis (1) by considering it as a direct
ompetition between percutaneous coronary intervention (PCI)
nd drug therapy. In the Discussion section of our article (1), we
arned against the risk of this kind of misinterpretation by writing:
It is important to note that the included randomized trials, and
onsequently the entire present meta-analysis, should not be
onsidered as a head-to-head comparison of 2 mutually exclusive
reatment strategies. On the contrary, all of them evaluated the
alue of the PCI-based strategy as an addition to medical therapy,
ecause patients in both study arms received medical treatment.”
e also acknowledged that advances in both pharmacological and
nterventional treatment of patients with coronary artery disease
ay have an impact, although the year of completion of patient
nrollment did not have a significant influence on the overall result
s shown by the meta-regression analysis.
The unique contribution of our meta-analysis was the ability to
ssess the impact of PCI on mortality, for which assessment, nonef the individual trials, including the COURAGE (Clinical
utcomes Utilizing Revascularization and Aggressive Drug Eval-
ation) trial, had sufficient power. Obviously, the performance of a
ew, large randomized trial with mortality as primary end point is
ore than welcome; but, until then, the results of our meta-
nalysis are the best available evidence on this topic and should
elp in guiding the treatment of patients with stable coronary
rtery disease.
As interventional cardiologists, we have recognized the great
linical benefits achieved with pharmacological therapy in patients
ith stable coronary artery disease. We prescribe the drugs
entioned in the letter of Dr. Arbab-Zadeh to almost all patients
rior to and after PCI. We closely work with noninterventional
ardiologists to provide optimal pharmacological and PCI-based
reatment to patients with stable coronary artery disease. However,
he benefit to these patients will be maximized if the merits of PCI
re duly recognized by the physicians who take care of patients
ith stable coronary artery disease.
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